Thus, the current studies suggest that germline mutations in DNA damage repair genes (BRCA1, BRCA2, ATM, and PALB2) and in DNA mismatch repair genes (MHL1, MSH2, MSH6, and PMS2) can drive the development of prostate cancer and this finding supports germline screening of pathogenic mutations. This evidence concerns the gene PMS2 and prostate carcinoma.